Skip to main content

Table 1 Baseline characteristics of patients of the full analysis set

From: Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency

 

Total population

Germany

Spain

N

1019

549

470

Age [years]

66.3 ± 9.7

65.4 ± 9.5

67.2 ± 9.7

% male

706 (69.3)

315 (57.4)

391 (83.2)

Duration of COPD [years]

6.7 ± 6.7

7.3 ± 6.8

5.9 ± 6.6

Emphysema

581 (57.0)

349 (63.6)

232 (49.4)

Chronic bronchitis

680 (66.7)

371 (67.6)

309 (65.7)

Bronchiectasis

75 (7.4)

25 (4.6)

50 (10.6)

Asthma

122 (12.0)

75 (13.7)

47 (10.0)

FEV1 [L]

1.47 ± 0.69

1.40 ± 0.72

1.55 ± 0.65

FEV1 [% predicted]

53.0 ± 20.7

50.2 ± 20.7

56.2 ± 20.3

FEV1/FVC [%]

53.1 ± 11.7

53.2 ± 12.2

53.0 ± 11.1

Exacerbations last year

564 (55.3)

273 (49.7)

291 (61.9)

Current smoker

267 (26.2)

135 (24.6)

132 (28.1)

Ex-smoker

721 (70.8)

395 (72.0)

326 (69.4)

Never smoker

31 (3.0)

19 (3.5)

12 (2.6)

Pack years

51.2 ± 36.4

45.4 ± 35.7

57.9 ± 36.1

  1. Data displayed are the mean ± standard deviation for continuous variables, and n (%) for categorical variables